

Early and Locally Advanced Breast Cancer (update) Committee meeting 1

Date: 05 & 06/09/16

Location: RCOG, London

Minutes: Confirmed

Committee members present:		
Jane Barrett		(Present for notes 1 – 17)
Anne Armstrong		(Present for notes 1 – 17)
Roger Hunt		(Present for notes 1 – 17)
Carmel Gulliver-Clarke		(Present for notes 12 – 17)
Imogen Locke		(Present for notes 1 – 17)
Sairanne Wickers		(Present for notes 1 – 17)
Linda Pepper		(Present for notes 1 – 17)
Ramsey Cutress		(Present for notes 1 – 17)
Marina Parton		(Present for notes 1 – 17)
Lisa Whisker		(Present for notes 1 – 17)
Sadaf Haque		(Present for notes 1 – 11)
Mia Rosenblatt		(Present for notes 1 – 17)
Ursula Van Mann		(Present for notes 1 – 17)
William Teh		(Present for notes 1 – 17)

In attendance:		
Clifford Middleton	NICE Guideline Commissioning Manager	(Present for notes 1 – 17)
Simran Chawla	NICE Patient Involvement Programme	(Present for notes 1 – 17)
John Graham	NGA Clinical Adviser	(Present for notes 1 – 11)
Angela Bennett	NGA Guideline Lead	(Present for notes 1 – 17)
James Hawkins	NGA Health Economist	(Present for notes 1 – 11)
Matthew Prettyjohns	NGA Senior Health Economist	(Present for notes 12 – 17)
Nathan Bromham	NGA Senior Systematic Reviewer	(Present for notes 1 – 11)
Laura O'Shea	NGA Systematic Reviewer	(Present for notes 1 – 17)
Ferruccio Pelone	NGA Assistant Reviewer	(Present for notes 1 – 17)
Lianne Gwillim	NGA Project Manager	(Present for notes 1 – 17)

Observers:

None

Apologies:

Carmel Gulliver-Clarke	Committee member	(Absent for notes 1 – 11)
Sadaf Haque	Committee member	(Absent for notes 12 – 17)
John Graham	NGA Clinical Adviser	(Absent for notes 12 – 17)
Matthew Prettyjohns	NGA Senior Health Economist	(Absent for notes 1 – 11)
Nathan Bromham	NGA Senior Systematic Reviewer	(Absent for notes 12 – 17)

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 1st meeting on Early and Locally Advanced Breast Cancer (update).

No members of the public asked to observe the meeting.

The Chair informed the Committee that apologies had been received. These are noted above.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Early and locally advanced breast cancer.

Name	Interest Declared	Type of interest		Date Declared	Decision taken
Lisa Whiskers	Works in a department (NHS), which on occasion receives financial reimbursement for costs to run feasibility assessment of new interventions (delivering treatment and collecting data for audit). Currently from IGEA for electrochemotherapy in advanced (skin metastases) breast cancer. In the last 12 months department has	Non-personal financial interest	Non Specific	August 2016	Declare and participate in discussions on all topics as guideline is not covering advanced breast cancer.

	also received money from Sebbin for Meso mesh feasibility audit and there is a contract with Novus Scientific for Tigr mesh feasibility audit, no money received in the department yet.				
Lisa Whiskers	Reviewer for Breast cancer care patient information leaflets. Reputational interest.	Non-financial interest	Non Specific	August 2016	Declare and participate in discussions on all topics as guideline is not covering patient information leaflets.
Lisa Whiskers	Steering group member for national iBRA audit. Audit assessing safety & comparing techniques for implant based breast reconstruction. Audit protocol recently accepted for publication. Data collection due to complete June 2016 and expected to be largest implant breast reconstruction series worldwide and publish 201. Audit is funded by The iBRA study is funded by the National Institute for Health Research, Research for Patient Benefit Programme (RfPB 0214-33065) and pump-priming awards from the Association of Breast Surgery (ABS) and the British Association of Plastic Reconstructive and Aesthetic Surgeons (BAPRAS). This money funds a research fellow and statistician for the project (both based in a different hospital).	Non-financial interest	Non Specific	August 2016	Declare and participate in discussions on all topics as guideline is not covering data collection for implant breast reconstruction.
Lisa Whiskers	Site PI (recruit patients, follow trial protocol locally) for Age Gap Trial (Bridging the Age Gap in Breast Cancer:	Non-financial interest	Specific	August 2016	Declare and participate in discussions on all topics as no supervisory

	Improving Outcomes for Older Women)				responsibility on trials.
Lisa Whiskers	Site PI (recruit patients, follow trial protocol locally) for LORIS (A Phase III Trial of Surgery versus Active Monitoring for Low Risk Ductal Carcinoma in Situ). Funded by NIHR	Non-financial interest	Specific	August 2016	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Lisa Whiskers	Gave a talk to the East Midlands Breast Cancer group educational meeting in April 16 on electrochemotherapy for metastatic breast cancer. No fees received	Non-financial interest	Specific	August 2016	Chair person's action to declare and participate in discussions on all topics.
Ramsey Cutress	Gave free advice to Inflatable Body Organs (public limited company who hold displays at events), on information to include on their stall and how to lay it out	Non-financial interest	Non Specific	August 2016	Declare and participate in discussions on all topics is not specific to the content of the guideline.
Ramsey Cutress	Secretary of the Academic and Research Committee for the Association of Breast Surgery	Non-financial interest	Non Specific	August 2016	Declare and participate in discussions on all topics is not specific to the content of the guideline.
Ramsey Cutress	Received travel and accommodation expenses from Royal College of Surgeons to teach at Advanced Management of Breast Disease Course	personal financial interest	Specific	August 2016	Declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
Ramsey Cutress	Assistant Editor for the Annals of the Royal College of Surgeons. Chooses peer reviewers for papers, receives reviews and makes recommendations to the Editor for which papers should be included in the journal.	Non-financial interest	Non Specific	August 2016	Declare and participate in discussions on all topics is not specific to the content of the guideline.
Ramsey Cutress	Trial Management Group (TMG) of Ephos-B – provide general advice on the trial, not involved designing the trial	Non Personal financial		August 2016	Declare and participate in discussions on all topics as no supervisory

	protocol.				responsibility on trials.
Ramsey Cutress	Independent Data Monitoring Committee of Sublime – checking trial data for patient safety issues. No involvement in designing protocol				Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Ramsey Cutress	Trial Steering Group POSNOC and iBRA – guide and plan studies. Was a co-applicant on a grant application to NIHR to fund his involvement in the iBRA audit	Non Personal financial		Aug ust 2016	Declare and participate as not funded by healthcare industry.
Ramsey Cutress	Local PI for multiple NIHR portfolio clinical trials – recruit patients at local centre and follow trial protocol. No involvement in designing trial protocol	Non Personal financial		Aug ust 2016	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Ramsey Cutress	Is a signatory on the breast and endocrine part of the University Hospital of Southampton Charitable fund. Not aware of any industry contributions to the fund. Used for education and development (e.g. attending conferences) and to pump prime purchase of equipment or services.	Non-financial interest		Aug ust 2016	Declare and participate in discussions on all topics is not specific to the content of the guideline.
Ramsey Cutress	Chief investigator on 2 NIHR studies (CANDO1 and BEGIN). Both studies looking at validating the accuracy of an electrical impedance machine to measure % body fat and muscle in people pre and post surgery and while on chemotherapy. Electrical impedance machine was donated to the department by Seca	Non Personal financial		Aug ust 2016	Declare and withdraw in discussions on all topics that look at body fat percentages or machines to measure body fat percentages.
Carmel	Received a fee from the	Personal	Specific	Aug	Declare and

Gulliver-Clarke	Royal Marsden for giving a lecture on survivorship in breast cancer in April 2016.	financial		ust 2016	participate in discussions on all topics as expenses not beyond a reasonable amount.
Carmel Gulliver-Clarke	Published papers/articles/book chapters on aromatase inhibitors, follow-up and survivorship in breast cancer. All were reviews of the available evidence – no conclusions about what should be done.	Non-financial interest		Aug ust 2016	Declare and participate in discussions on all topics is not specific to the content of the guideline.
Imogen Locke	Received travel and accommodation from Ipsen to attend a meeting in April 2016 and give an invited presentation on breast radiotherapy	Personal Financial	Specific	Aug ust 2016	Declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
Imogen Locke	Co-investigator (follow trial protocol locally) on: <ul style="list-style-type: none"> HEARTSPARE (investigating the impact of different heart-sparing breast radiotherapy techniques upon normal-tissue doses). Funded by NIHR 	Non Personal financial	Specific	Aug ust 2016	Declare and participate as not funded by healthcare industry. Declare and participate as not funded by healthcare industry.
Imogen Locke	Co-investigator (follow trial protocol locally) on: <ul style="list-style-type: none"> PRADA (Primary Radiotherapy And DIEP flap Reconstruction Trial). Funded by Imperial College Healthcare NHS Trust 	Non Personal financial	Specific	Aug ust 2016	Declare and participate as not funded by healthcare industry.
Imogen Locke	Fundholder for a research fund within the Royal Marsden Charitable funds. Used to support research (i.e. purchase equipment). No industry contributions to the fund.	Personal Financial		Aug ust 2016	Declare and participate as not funded by healthcare industry.

Imogen Locke	Wrote to NICE disagreeing with the results of the MTA on the Intrabeam radiotherapy system for treating early breast cancer	Non-financial interest	Specific	August 2016	Declare and participate in discussions on all topics as on-going TA's will not be looked at within the guideline.
Roger Hunt	Received travel expenses from Roche to attend a meeting in September 2015 about HER2 testing in triple negative breast cancer	Personal Financial	Specific	August 2016	Declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
Roger Hunt	Provide a diagnostic histopathology service as part of his private medical practice. Service provided is identical to that of NHS practice	Personal Financial	Specific	August 2016	Declare and participate in discussions on all topics as private practice is aligned with standard NHS care
Roger Hunt	Supports an ongoing local clinical research by selecting and submitting patients' tissue for analysis once they have been entered into breast and GI cancer clinical trials. This has included sampling cases, retrieving tissue and providing reports for the Tip, Marginprobe, HERA, TransHERA, ephos B, neoTango, POSH, TransATAC, Poetic, Supremo and Foxtrot trials.	Non Personal financial		August 2016	Declare and participate in discussions on all topics as only involvement in trials is to submit tissue samples for analysis.
Roger Hunt	Expert advisor to NICE on a technology appraisal on vacuum assisted biopsy.	Non Personal financial	Non Specific	August 2016	Declare and participate in discussions on all topics as on-going TA's will not be looked at within the guideline
Marina Parton	On the steering group for the Eisai First Thoughts educational meeting on metastatic breast cancer. Meeting is held every January and participating on steering group involves meeting 3	Personal financial		August 2016	Declare and participate in discussions on all topics as expenses not beyond a reasonable amount.

	times a year to arrange the event. Last fee received personally was in January 2016. All fees for subsequent meetings have been given to Breast Unit Research Fund.				
Marina Parton	Received a fee from Roche in June 16 for giving an SpR masterclass on HER2 positive advanced breast cancer treatments. Fee was given to Breast Unit Research Fund	Personal financial		August 2016	Declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
Marina Parton	Novartis funded accommodation to ASCO in June 2015	Personal financial		August 2016	Declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
Marina Parton	Amgen funded flights and accommodation to ESMO in September 2015	Personal financial		August 2016	Declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
Marina Parton	Named by Eisai as a subject expert for the forthcoming NICE TA on Eribulin	Non Personal financial		August 2016	Declare and participate in discussions on all topics as on-going TA's will not be looked at within the guideline.
Marina Parton	May be involved in future meeting about cancer pathways in breast cancer and metastatic treatments, organised by Piere Fabre. Would be eligible for a fee but this would be donated to the Breast Unit Research Fund, not received directly.	Personal financial		August 2016 August 2016	If involved - Declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
Marina Parton	Have reviewed information sheets and given talks for Breast Cancer Care and	Personal non-financial		August 2016	Chair person's action to declare and participate in discussions on all

	Macmillan – no fees received.				topics
Marina Parton	<p>Principle investigator on the following trials (not involved in designing trial protocol):</p> <ul style="list-style-type: none"> • OLYMPIA (Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer). Funded by Breast International Group, Frontier Science & Technology Research Foundation, Inc., NRG Oncology, Myriad Genetic Laboratories, Inc., Br.E.A.S.T. - Data Center & Operational Office Institut Jules Bordet 	Non Personal financial		Aug ust 2016	Declare and participate in discussions on all topics as individual has no supervisory responsibility for the trial.
Marina Parton	<p>Principle investigator on the following trials (not involved in designing trial protocol): KAITLIN (A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2 POSITIVE PRIMARY BREAST CANCER).</p>	Non Personal financial		Aug ust 2016	Declare and participate in discussions on all topics as individual has no supervisory responsibility for the trial.

	Funded by Roche				
Marina Parton	<p>Principle investigator on the following trials (not involved in designing trial protocol):</p> <ul style="list-style-type: none"> D-CARE (Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy). Funded by Amgen 	Non Personal financial		Aug ust 2016	Declare and participate in discussions on all topics as individual has no supervisory responsibility for the trial.
Marina Parton	<p>Principle investigator on the following trials (not involved in designing trial protocol):</p> <ul style="list-style-type: none"> AFFINITY (A prospective, randomized multicenter, multinational, two-arm comparison of chemotherapy plus trastuzumab given for a total of one year versus chemotherapy plus trastuzumab and pertuzumab given for a total of one year as adjuvant therapy in patients with operable HER2-positive primary breast cancer). Funded by Roche 	Non Personal financial		Aug ust 2016	Declare and participate in discussions on all topics as individual has no supervisory responsibility for the trial.
William Teh	Honorarium in Oct 15 from Hologic for giving a lecture on vacuum biopsy and best practice in breast cancer –	Personal financial		Aug ust 2016	Declare and withdraw from discussions on vacuum biopsy until Oct 16.
William Teh	Sat on a panel about Oncotype DX. Received expenses from Genomic	Personal financial		Aug ust 2016	Declare and participate in discussions on all

	Health.				topics as expenses not beyond a reasonable amount.
William Teh	Does private practice where sees breast cancer patients. Uses HIFU on private patients which is not commonly used in NHS patients.	Personal financial		Aug ust 2016	Declare and withdraw from discussions on where HIFU is an intervention.
William Teh	Recruits patients to the FH02 trial.	Non personal financial		Aug ust 2016	Declare and participate in discussions on all topics as individual has no supervisory responsibility for the trial.
William Teh	Local PI for the LORIS trial (administers things locally, no involvement in trial protocol).	Non personal financial		Aug ust 2016	Declare and participate in discussions on all topics as individual has no supervisory responsibility for the trial.
William Teh	Local co-investigator for MEMO50 trial (just reports imaging of patients involved).	Non personal financial			Declare and participate in discussions on all topics as individual has no supervisory responsibility for the trial.
William Teh	Local PI for the NHS Breast Screening Age Extension trial (administers things locally, no involvement in trial protocol).	Non personal financial		Aug ust 2016	Declare and participate in discussions on all topics as individual has no supervisory responsibility for the trial.
William Teh	Is a signatory on a charitable fund used for CPD expenses for registrars and consultants – no contributions from the industry to the fund	Personal non-financial		Aug ust 2016	Declare and participate as not funded by healthcare industry.
Sairanne Wickers	Attended NICE meeting on behalf of SCoR 11 th November 2015 as an observer of the NICE Quality Standards advisory committee for breast cancer. Feedback report	Non personal financial		Aug ust 2016	Declare and participate in discussions on all topics as expenses not beyond a reasonable amount.

	submitted to SCoR.				
Sairanne Wickers	NICE expert advisor on the Intrabeam MTA	Personal non-financial		August 2016	Declare and participate in discussions on all topics as Intrabeam MTA is not the focus of the guideline.
Sairanne Wickers	Received travel, accommodation and conference fee from Oncology Imaging Systems to attend ESTRO in May 16	Personal financial		August 2016	Declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
Sairanne Wickers	Single centre study on staff volunteers to look at the accuracy of the Varian breast hold system. Done as part of Masters dissertation – designed protocol. No industry funding. Now has ethics approval to extend study to look at patients.	Personal non-financial		August 2016	Chair persons action to declare and participate in discussions on all topics
Sairanne Wickers	Centre is participating in the IMPORT-HIGH trial. As part of this have collected data on radiotherapy accuracy. Hoping to write this up and publish.	Personal non-financial		August 2016	Chair persons action to declare and participate in discussions on all topics
Sairanne Wickers	Took part in RCR consensus meeting on radiotherapy treatment for breast cancer in March 16. Represented the views of the centre – not a personal perspective			August 2016	Chair persons action to declare and participate in discussions on all topics.
Mia Rosenblatt	Role is Assistant Director of Policy and Campaigns for Breast Cancer Now. Heads up all policy and public campaigns – covering issues related to breast cancer health and research (no focus on any specific trials). Has been quoted on press			August 2016	

	releases				
	Oncotype DX http://breastcancernews.org/news-and-blogs/news/breast-cancer-campaign-comments-on-ncotype-dx-test				Chair persons action to declare and participate in discussions on all topics.
	Being able to contact a CNS http://breastcancernews.org/news-and-blogs/news/comment-on-national-cancer-patient-experience-survey				Chair persons action to declare and participate in discussions on all topics.
	Bisphosphonates (indirectly) http://breastcancernews.org/news-and-blogs/news/bill-to-revolutionise-access-to-breast-cancer-treatments				Chair persons action to declare and participate in discussions on all topics.
	http://www.independent.co.uk/life-style/health-and-families/health-news/lives-will-be-lost-unless-the-government-acts-on-off-patent-drugs-charities-warn-9841994.html				Chair persons action to declare and participate in discussions on all topics.
Mia Rosenblatt	Partner has shares in Glaxo Smith Kline and Futura Medical.	Personal financial		August 2016	Declare and withdraw from discussions of any topics that include interventions made by GSK or Futura Medical
3. Minutes of last meeting					
No minutes as this is the first meeting.					
4. Presentations					
<p>The Chair introduced Clifford Middleton, who have a presentation on an introduction to NICE.</p> <p>The Chair introduced John Graham, who have a presentation on an introduction to NGA.</p>					

The Chair introduced Lianne Gwillim, who have a presentation on the timetable for the guideline and housekeeping.

The Chair introduced Simran Chawla, who have a presentation on Patient/Carer involvement in guideline development

The Chair introduced Nathan Bromham, who have a presentation on Guidance development methodology, from evidence to recommendations

The Chair introduced James Hawkins, who have a presentation on Health Economics in NICE guidelines.

5. Questions and discussion

The Committee discussed the draft review questions and agreed the revised question, PICO, Health Economic priority, lead and for these questions.

6. Any other business

No service user or carer concerns were raised.

Date of next meeting: 31st October 2016

Location of next meeting: RCOG, London